Vyleesi Fact Sheet

What is bremelanotide (Vyleesi)?  Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women. Overview  Bremelanotide is designed to be used on an “as-needed” basis about 45 minutes before sexual activity is expected.  It has to be injected, and an … Continued

Addyi Health Fact Sheet

  What is Flibanserin (Addyi)? Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.  Although the drug is ineffective and potentially dangerous, the agency approved it in 2015 over the objections of the NWHN and … Continued

Flibanserin Update: Health and Safety Concerns Continue to be Profound

On Monday, JAMA Internal Medicine published a systematic review evaluating the safety and efficacy of flibanserin, a drug purported to treat Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. Unsurprisingly, the researchers reported that flibanserin’s benefits are “are marginal, particularly when taking into account the concurrent occurrence of adverse events.” Further, the researchers reported “the … Continued

Consumer Alert — Pass on the Pink Pill Or Pass Out

EMERGENCY WOMEN’S HEALTH ALERT ON ADDYI The New Sex Drug for Women The National Women’s Health Network is warning all women about the health risks of the new “pink pill” – known as flibanserin and branded as Addyi – alleged to boost female libido. Rather than rely on drug company marketing, NWHN recommends that women … Continued

Flibanserin: the FDA’s Approval is Bad Science and Bad Precedent

This year, the Food and Drug Administration (FDA) made history — for all the wrong reasons. After a five-year battle for approval, on August 18th, the agency succumbed to a relentless and clever public relations campaign and approved flibanserin, the first drug to treat hypoactive sexual desire disorder (HSDD) in women. That means that, as … Continued

The National Women’s Health Network Continues to Express Deep Concern Over Addyi’s Safety

FOR IMMEDIATE RELEASE  Contact:   Christina Cherel at ccherel@nwhn.org or (202) 682-2640   Washington, D.C. – Tomorrow, the first FDA-approved drug to treat hypoactive sexual desire disorder (HSDD) in premenopausal women will be available by prescription. The National Women’s Health Network (“the Network”) remains deeply concerned over the unanswered questions regarding Addyi’s interaction with alcohol and the drug’s … Continued

Top 10 Things to Know about Today’s Sex Drive Drugs

  Addyi (flibanserin) and Vyleesi (bremelanotide) are FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.  Neither of these drugs is a “Viagra for women.” Though both medications have taken their turns being dubbed the “female Viagra” in media reports, they are very different from the little blue pill. Viagra helps … Continued

National Women’s Health Network Urges the FDA to Oppose Twice-Rejected Female Sex Drug

FOR IMMEDIATE RELEASE  Contact: Cindy Pearson at 301-938-0356 or Coco Jervis at 202-407-0788   The National Women’s Health Network (“the Network”) urges the FDA to oppose the approval of Sprout Pharmaceutical’s female sexual dysfunction drug flibanserin. The Network has come to this position after careful consideration of newly disclosed research and thorough evaluation of the … Continued